Carotid atherosclerosis
Conditions
Interventions
Puerarin group:Puerarin capsule (50mg/time), 3 times a day + Statins
Control group:Statins
Sponsors
Zhujiang Hospital, Southern Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients (male/female) between 40 and 80 years of age; 2. The distance between the outer membrane interface of the common carotid artery and the endometrial interface (IMT) = 1.0 mm or at least one measurable plaque; 3. Dyslipidemia metabolism: TG >200 mg/dL, LDL-C>130 mg/dL, TC>200 mg/dL and HDL-C<40 mg/dL for men and <50 mg/dL for women; 4. Voluntarily participate in this clinical trial, understand and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with hepatic impairment (SGOT or SGPT levels > 3 Upper Limit of Normal (ULN)) or renal impairment (serum creatinine =2.0 mg/dl), patients with any other severe systemic illness such as malignancy, severe neuroendocrine system diseases and mental disease; 2. Patients who have taken any antibiotics or probiotics or prebiotic preparations within one month; 3. Patients who have taken any Chinese traditional patent Medicine or Chinese traditional medicine within one month; 4. Pregnancy or preparation for pregnancy and lactation women; 5. Allergic persons, or those known to be allergic to puerarin; 6. patients who are participating in another clinical trial within 1 month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma TMAO concentration;16S rRNA gene sequencing analysis of stool;Fecal TMA concentration; | — |
Countries
China
Contacts
Public ContactMinsheng Chen
Southern Medical University
Outcome results
None listed